Creative Medical Technology Holdings, Inc. Unrealized Gain (Loss) on Derivatives
Creative Medical Technology Holdings, Inc. (CELZ) reported Unrealized Gain (Loss) on Derivatives of -$26.73 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-30.
Discontinued › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnDerivatives · last filed 2022-03-30
- Creative Medical Technology Holdings, Inc. unrealized gain (loss) on derivatives for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- Creative Medical Technology Holdings, Inc. unrealized gain (loss) on derivatives for the quarter ending 2021-09-30 was $179.58K.
- Creative Medical Technology Holdings, Inc. unrealized gain (loss) on derivatives for the quarter ending 2021-06-30 was $2.25M.
- Creative Medical Technology Holdings, Inc. unrealized gain (loss) on derivatives for the quarter ending 2021-03-31 was -$29.16M.
- Creative Medical Technology Holdings, Inc. unrealized gain (loss) on derivatives for fiscal 2021 was -$26.73M, a 183.22% decline from fiscal 2020.
- Creative Medical Technology Holdings, Inc. unrealized gain (loss) on derivatives for fiscal 2020 was $32.12M.
| Period end | Unrealized Gain (Loss) on Derivatives 3 month | Unrealized Gain (Loss) on Derivatives 6 month | Unrealized Gain (Loss) on Derivatives 9 month | Unrealized Gain (Loss) on Derivatives 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $179.58K derived: sum of 2 quarters · filed 2022-03-30 | $2.43M derived: sum of 3 quarters · filed 2022-03-30 | -$26.73M 10-K · filed 2022-03-30 |
| 2021-09-30 | $179.58K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $2.43M derived: sum of 2 quarters · filed 2021-11-15 | -$26.73M 10-Q · filed 2021-11-15 | $9.78M derived: sum of 4 quarters · filed 2021-11-15 |
| 2021-06-30 | $2.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | -$26.91M 10-Q · filed 2021-08-16 | $9.60M derived: sum of 3 quarters · filed 2021-08-16 | $8.58M derived: sum of 4 quarters · filed 2021-08-16 |
| 2021-03-31 | -$29.16M 10-Q · filed 2021-05-17 | $7.35M derived: sum of 2 quarters · filed 2021-05-17 | $6.33M derived: sum of 3 quarters · filed 2021-05-17 | |
| 2020-12-31 | $36.51M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-17 | $35.49M derived: sum of 2 quarters · filed 2021-03-17 | $32.12M 10-K · filed 2021-03-17 | |
| 2020-09-30 | -$1.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | -$4.39M 10-Q · filed 2020-11-13 | ||
| 2020-06-30 | -$3.37M 10-Q · filed 2020-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Silexion Therapeutics Corp (SLXN) | $0.001B |